BridgeMD
A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
EU CTIS ID: 2023-509572-42-00
What this study is testing
To evaluate the safety and tolerability of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with advanced RAS- mutated NSCLC
- Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients that are at least 18 years old. Patients that have NSCLC with certain RAS mutations. Patients that have NSCLC that is unlikely to be cured and has spread to other body parts. Patients that have received prior cancer treatment. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. Patients that have adequate organ function (bone marrow, liver, kidney).
You likely can't join if
- 1. Participants that have primary brain and spinal cord tumor spreading to other body parts. 2. Participants that have gastrointestinal problems that may affect absorption of RMC-6236. 3. Participants that had any major surgery in the last 4 weeks. 4. Participants that have have previously taken targeted therapy for RAS mutation. 5. Participants that have any other medical condition that may interfere with the study drugs.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.